[{"orgOrder":0,"company":"University of California","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"CNDR-51997","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ National Institute on Aging"},{"orgOrder":0,"company":"University of California","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of California \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ Inapplicable"},{"orgOrder":0,"company":"University of California","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"University of California \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ Inapplicable"},{"orgOrder":0,"company":"University of California","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ramipril","moa":"ACE receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of California \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ Inapplicable"},{"orgOrder":0,"company":"University of California","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Degarelix Acetate","moa":"GnRH receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ Inapplicable"},{"orgOrder":0,"company":"UCLA","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCLA \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"UCLA \/ National Institutes of Health"},{"orgOrder":0,"company":"University of California","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of California \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of California \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"University of California","sponsor":"Releviate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"RLVT-9-01","moa":"MMP-9","graph1":"Neurology","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ Releviate Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ Releviate Therapeutics"},{"orgOrder":0,"company":"University of California","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Thrixopelma Pruriens Venom Peptide","moa":"NaV1.7 channel","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"University of California \/ AmbioPharm"}]

Find Clinical Drug Pipeline Developments & Deals by University of California

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : The proceeds will be used to prepare a potential disease-modifying Alzheimer’s treatment, CNDR-51997, which prevented tau from becoming detached from microtubules, for future clinical trials.

                          Product Name : CNDR-51997

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 21, 2024

                          Lead Product(s) : CNDR-51997

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : National Institute on Aging

                          Deal Size : $6.9 million

                          Deal Type : Funding

                          blank

                          02

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Researchers have utilized a venom peptide originally isolated from the Peruvian green velvet tarantula (Thrixopelma pruriens) that blocks Nav1.7 voltage-gated ion channels, an ion channel important in pain signaling.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          July 20, 2021

                          Lead Product(s) : Thrixopelma Pruriens Venom Peptide

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : AmbioPharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : The UCSF team used protein engineering to make a synthetic nanobody that prevents the spike protein on the surface of SARS-CoV-2, the virus that causes COVID-19, from binding to healthy cells and infecting them.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 08, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Releviate gets an exclusive license for two patents, RLVT-9-01 (anti-MMP-9 antibody) and RLVT-14-02 (anti-MMP-14 antibody) pending human monoclonal antibodies developed by researchers at the University of California, Riverside and Duke University.

                          Product Name : RLVT-9-01

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          October 28, 2020

                          Lead Product(s) : RLVT-9-01

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Releviate Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : The five-year grant, part of an NIH effort to develop gene-engineering technologies to cure HIV/AIDS, will fund a collaboration among UCLA; CSL-Behring, to investigate and further develop an immunotherapy known as CAR T.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 15, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : National Institutes of Health

                          Deal Size : $14.0 million

                          Deal Type : Funding

                          blank

                          06

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Under the terms and conditions of the agreement, Cytovia will have an exclusive option to license certain patentable inventions developed as part of the research program.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 01, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Cytovia Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          07

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : The new trial will evaluate the impact of temporarily suppressing male hormones on decreasing the Covid-19 severity to help patients discharge from hospital faster, reduce the need for incubation, and improve mortality.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          May 18, 2020

                          Lead Product(s) : Degarelix Acetate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : University of California San Diego School of Medicine launch a clinical trial to asses ACE inhibitor drug used to treat heart conditions can lower complexities in Covid-19 infection.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 30, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Ramipril will be assessed for its potential to decrease the severity of Covid-19, lower intensive care unit admission rates, mechanical ventilators use, and all-cause mortality.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 05, 2020

                          Lead Product(s) : Ramipril

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank